Recent investigations on retatruded, a dual activator for incretin hormone and GIP, demonstrate encouraging findings in treating obesity and type 2 glucose intolerance. Early information from clinical trials reveal substantial diminutions in body mass and improved glucose regulation. Further research is centered on long-term harmlessness and useful